Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools


You are here: Home / Members / Federico Innocenti
Federico  Innocenti

Federico Innocenti

  • MD, PhD
  • Clinical Research

  • Associate Professor
  • UNC-Chapel Hill
  • 919-966-9422
  • 1014 Genetic Medicine Bldg Chapel Hill, NC 27599

Area of Interest

As a translational physician scientist, my career goal is to consolidate and expand a current program of research aimed at discovering effective strategies for individualizing therapy for cancer patients. This program aims to reach this goal through the identification of genetic determinants of outcomes of chemotherapy in cancer patients, both in the laboratory and the clinic. The lab discovers and tests the biological function of novel germline genetic variants that might serve as markers of severe toxicity and survival in cancer patients treated with angiogenesis inhibitors and other chemotherapy agents. This research integrates whole-genome strategies with more targeted, gene-based strategies. It requires multidisciplinary efforts that span from the discovery of potential genetic biomarkers to validation of their clinical utility in intervention trials in cancer patients.

Prospective Research Statement

Translational program in cancer pharmacogenomics

This program integrates genomic investigation into clinical studies of patients treated with chemotherapy. The results of these investigations will be also supported by the functional evaluation of biological mechanisms of gene variation.

A framework of clinical, epidemiology, and laboratory studies has been already built, and some of these studies are ongoing. The program is articulated in three main themes:

Theme 1: Clinical genome-wide and candidate gene investigations of anticancer drugs. These studies provide the platform for discovery and implementation of genomic markers of individualize therapy in oncology. GWAS, sequencing, and targeted intervention studies are ongoing.

Theme 2: Functional genetics of angiogenesis genes. This research addresses how functional germline variants of VEGF-pathway genes affect the in vitro action of VEGF-pathway inhibitors and gene expression in tumors. The results of these studies propose novel biomarkers for clinical investigation and will enrich the clinical associations of Theme 1.

Theme 3: Genome-wide regulation of gene expression in the human liver. This project provides a comprehensive assessment of the heritable component of gene expression variation in the liver. These results represent a useful resource for UNC faculty and the scientific community as a whole. They serve as the knowledge basis for any pharmacogenetic study (like those in Theme 1).

Awards and Honors

One-year fellowship award for training in a foreign institution awarded by the National Research Council, Rome, Italy (1998 - 1999)

Award for training in a foreign institution by the Italian Society of Pharmacology (1998 - 1999)

Cancer Research Foundation, Young Investigator Award (2006)

American Society of Clinical Pharmacology and Therapeutics Leon I Goldberg Young Investigator Award (2012)

Alliance of Clinical Trials in Oncology: Chair of the Gastrointestinal Solid Tumor Correlative Science Group (2011 – present)

American Society of Clinical Pharmacology and Therapeutics (ASCPT): Chair of the Oncology Section (2012 - present)

NCI: Gastrointestinal Steering Committee – Colon Task Force – Translational Science Representative (2013 - present)